Loading clinical trials...
Loading clinical trials...
An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
Conditions
Interventions
atumelnant (CRN04894)
Locations
9
United States
Crinetics Study Site, Minneapolis, Minnesota 55454
Minneapolis, Minnesota, United States
Crinetics Study Site
Morehead City, North Carolina, United States
Crinetics Study Site
Córdoba, Córdoba Province, Argentina
Crinetics Study Site
Botucatu, São Paulo, Brazil
Crinetics Study Site
São Paulo, Brazil
Crinetics Study Site
Munich, Bavaria, Germany
Start Date
February 25, 2025
Primary Completion Date
November 1, 2027
Completion Date
November 1, 2027
Last Updated
September 23, 2025
NCT06573723
NCT03760835
NCT04463316
NCT07536269
NCT05907291
NCT06449456
Lead Sponsor
Crinetics Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions